Research Article

Evaluating eating behaviour, energy homeostasis and obesity in childhood onset craniopharyngioma: A feasibility study

Elanor C. Hinton^a, Fiona E. Lithander ^{c, d, e}, Rebecca L. Elsworth^a, Katherine Hawton^b, Kruthika Narayan ^b, Sophie Szymkowiak^a, Holly L. Bedford^a, Nimra Naeem^c, Ruth Elson^b, Tashunka Taylor-Miller^b, Julian P. Hamilton-Shield^a, Elizabeth C. Crowne^b

^a NIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, U.K.

^b Department of Paediatric Endocrinology & Diabetes, Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.

^c Bristol Medical School, University of Bristol, Bristol, U.K.

^d Liggins Institute, University of Auckland, New Zealand

^e Department of Nutrition and Dietetics, University of Auckland, New Zealand

Short Title: Eating behaviour, energy homeostasis and obesity in childhood craniopharyngioma

Corresponding Author:

Dr Elanor Hinton NIHR Bristol Biomedical Research Centre Nutrition Theme, University of Bristol, Education and Learning Centre, Upper Maudlin Street, Bristol, BS2 8AE. U.K. Tel: +44 117 455 4558 E-mail: Elanor.hinton@bristol.ac.uk

Number of Tables: 6 Number of Figures: 2 Word count: 4945 Keywords: Craniopharyngioma, obesity, eating behaviour, hyperphagia, energy

1 Abstract

2 Introduction: Craniopharyngiomas are rare brain tumours (incidence 1.1-1.7 cases/million/year). 3 Although benign, craniopharyngioma causes major endocrine and visual morbidities including 4 hypothalamic obesity, yet mechanisms leading to obesity are poorly understood. This study 5 investigated the feasibility and acceptability of eating behaviour measures in patients with 6 craniopharyngioma, to inform the design of future trials. 7 8 Methods: Patients with childhood-onset craniopharyngioma and controls matched for sex, pubertal 9 stage and age were recruited. After an overnight fast, participants received the following measures: 10 body composition, resting metabolic rate, oral-glucose-tolerance-test including MRI (patients only), 11 appetite ratings, eating behaviour and quality of life questionnaires, ad libitum lunch, and an 12 acceptability questionnaire. Data are reported as median ± IQR, with effect size measure (Cliff's 13 delta) and Kendall's Tau for correlations, due to the small sample size. 14 15 Results: Eleven patients (median age=14yrs; 5F/6M) and matched controls (median age=12yrs; 16 5F/6M) were recruited. All patients had received surgery and 9/11 also received radiotherapy. Hypothalamic damage post-surgery was graded (Paris grading): grade 2 n=6; grade 1 n=1; grade 0 17 18 n=2. The included measures were deemed highly tolerable by participants and their parent/carers. 19 Preliminary data suggests a difference in hyperphagia between patients and controls (d=0.5), and a 20 relationship between hyperphagia with body mass index (BMISDS) in patients (τ =0.46). 21 22 Discussion: These findings demonstrate that eating behaviour research is feasible and acceptable to 23 craniopharyngioma patients and there is an association between BMISDS and hyperphagia in 24 patients. Thus, food approach and avoidance behaviours may be useful targets for interventions to 25 manage obesity in this patient group. 26 27 28

29 Introduction

Craniopharyngiomas are embryological, histologically benign brain tumours, located in the sellar and parasellar regions (1). The incidence is 0.5-2 new cases per million persons per year (2), of which 30-50% occur in children and adolescents (3). Survival is high, at over 98% (4), but with significant levels of morbidity. Craniopharyngioma and its treatments, including gross total resection, limited resection and/or irradiation (5), commonly lead to endocrine deficiencies, visual impairment and obesity (6).

36

Obesity is a common feature of childhood craniopharyngioma (50%), which may develop several
years before diagnosis (7), though there is a marked increase in prevalence (22-62%) following
surgery (8, 9). Obesity in childhood craniopharyngioma is associated with a high risk of multisystem
morbidity (10, 11), metabolic syndrome (12), cardiovascular disease (13) and mortality (14). Yet,
there is limited evidence for effective weight loss interventions (15) and pharmacological treatments
(16, 17) in this population.

43

44 Mechanisms leading to obesity and altered energy homeostasis in craniopharngioma are complex, 45 yet understudied. Hypothalamic involvement of the tumour or damage to the hypothalamus 46 following treatment is associated with severe obesity (7) and the degree of obesity is positively 47 correlated with extent of hypothalamic damage (18, 19). Evidence to date, suggests an association 48 between overweight and obesity with hyperphagia (20-22), contrasting with other evidence that 49 presents lower energy and fat intake compared to body mass index (BMI) matched controls (23). The 50 extent of hypothalamic damage across patient groups (24) or methodological limitations could 51 explain the discrepancy between these findings, including the number of patients willing and able to 52 accurately complete self-reported dietary intake diaries (21). Alternative measures that could be 53 employed to assess eating behaviour are the ad libitum meal, which has only been used by one 54 research group with craniopharyngioma patients to date (17, 25), and validated psychological 55 questionnaires that have been specifically designed to measure different eating behaviour traits (e.g. 56 Hyperphagia (26); Child Eating Behaviour Questionnaire (27)). A scoping review exploring the current 57 literature addressing eating behaviour and psychological mechanisms associated with obesity in 58 patients with craniopharyngioma is currently in progress (28). 59

Beyond eating behaviour per se, evidence thus far suggests a reduction in energy expenditure
following craniopharyngioma or its treatment (29-31), which may be mediated by damage to

efferent sympathetic nervous system pathways in the hypothalamus (32). A preliminary study using
functional neuroimaging suggested patients with craniopharyngioma may have altered food cue
reactivity (25). Moreover, there is mixed evidence for differences in peripherally secreted hormones,
such as leptin, GLP-1, insulin, PYY and ghrelin (19, 33-35). Inconsistencies in findings could be due to
the differing extent of hypothalamic damage or levels of BMI-SDS in patient groups across studies.
Obesity in children and young people with craniopharyngioma causes substantial personal and
parental worry (36). Quality of life (QoL) is negatively affected overall by craniopharyngioma (37),

and obesity has been found to be a significant predictor of long-term QoL in paediatric patients (38).

71 QoL as rated by the parents has been found to be more impaired compared to their child's rating

72 (36, 39). Therefore, investigating what factors may be associated with poor QoL in

craniopharyngioma is an important focus of research to inform future interventions.

74

75 This feasibility study was designed to address four objectives to assess: (i) accessibility to medical 76 records to fully characterise the patients' eating behaviour and obesity to date, (ii) recruitment to 77 research in this young patient group, and (iii) their tolerability and acceptability of a range of 78 measures. By analysing the preliminary data from this study, including data from a control group matched on age, sex and pubertal stage, we also addressed the final objective (iv) to assess which 79 80 measures might be the 'most informative' to characterise the eating behaviours of patients with 81 childhood-onset craniopharyngioma to take forward into a future, multicentre trial. By 'most 82 informative', we mean whether preliminary evidence was seen for a difference between those with 83 and without craniopharyngioma, and/or a relationship with BMI SDS. This paper focuses on 84 feasibility and acceptability of all the included measures, and preliminary data from the energy 85 intake and expenditure measures. The larger dataset including neuroimaging and measures of 86 peripheral entero-endocrine hormones results will be presented elsewhere. This study was 87 registered on ISRCTN database (https://doi.org/10.1186/ISRCTN86005167).

88

89 Materials and Methods

The study was conducted between January 2019 and October 2021. The protocol and associated
documentation were approved by South West - Frenchay Research Ethics Committee (approval
number 18/SW/0235; Nov 2018). When seeking informed consent, an age-appropriate patient
information sheet was sent out to participants and parents/carers at least two weeks in advance of
their next appointment, to allow time to consider participation. Potential participants and their

95 parents were given the opportunity to ask any questions and the study was explained in a way the 96 potential participant could understand. If participants aged 16 or over agreed to take part, they gave 97 written informed consent on the form provided. Parents/carers of participants aged 16 or over were 98 also informed about the study if the participants were happy for their parents/carers to be 99 informed. If parents/carers were present at the appointment, they were also asked to give their 100 consent (which was the case for the only 16+ participants in the study). Parents/carers were invited 101 to provide written informed consent for those participants aged 15 or under, who provided assent to 102 participate. Participants were free to withdraw at any time during the study without any impact on 103 their medical care.

104

105 Participants

106 Inclusion criteria: Craniopharyngioma diagnosed under 18 years of age, now currently aged 7-25

107 years. Exclusion criteria: clinically unwell requiring hospital or intensive treatment; unwilling to fast;

108 significant visual impairment so unable to undertake food cue reactivity tasks; patients for whom it

109 would be unsafe to have an MRI including those with metal implants, tattoos with metallic ink, or

110 metal body piercings which cannot be removed; pregnancy to avoid harm to the fetus;

111 claustrophobia in the closed MRI environment or unable to tolerate the MRI scanner; weight above

112 152kg and/or girth greater than 210cm due to size limitations of MRI scanner.

113

Following recruitment of the patient group, control participants were recruited matched on (i) sex (male/female at birth), (ii) pubertal stage (pre-pubertal, pubertal, post-pubertal), and (iii) age (within 12 months, where possible following ii). Based on the same exclusion criteria, the control group were recruited from online adverts on University of Bristol websites and on social media.

118

119 Measures

Body composition: Height (to nearest 1mm) and weight (to nearest 1g) were measured using a
stadiometer and calibrated weighing scales. The LMS Growth method was used to calculate body
mass index standard deviation score (BMISDS; (40)). In addition, body composition was measured
using multifrequency bioelectrical impedance (Tanita MC-780).

124

Resting metabolic rate (RMR): RMR was measured using indirect calorimetry (Cosmed K4b2). The equipment was calibrated prior to each data collection to ensure accuracy. Once the appropriatesized mask had been fitted, participants lay supine to relax and asked to stay quiet and still for the duration of the measurement (20 minutes). The flattest portion (10 minutes) of the collected data,

as depicted graphically in the K4b2 software, was selected for the calculation of RMR in the Cosmedsoftware.

131

132 Oral glucose tolerance test (OGTT) & Magnetic Resonance Imaging (MRI): All participants consumed 133 a glucose drink (oral glucose solution 1.75g/kg up to maximum of 75g). Computerised, subjective 134 measures of hunger, fullness, thirst, and nausea were taken at baseline, 30-, 60-, 90- and 120minutes post glucose consumption using visual analogue scales (100mm line with endpoints of 'Not 135 136 at all' and 'Extremely'). Blood samples were collected from patients only, via an intravenous cannula 137 at baseline, 30-, 60-, 90- and 120-minutes post glucose consumption to measure glucose, insulin, 138 ghrelin, GLP1 and PYY. Leptin, full blood count (FBC) and electrolytes (U&Es) were also measured at 139 baseline. 140 Patients underwent two MRI scans in 30-minute scan blocks: at baseline prior to the glucose drink, 141 and 60 minutes post glucose consumption, and compared with historical control data from a 142 previous study with identical methodology (41). This research scan included a food cue reactivity 143 task, which was given to the control participants outside of the MRI scanner. Note that the OGTT 144 and associated methodology are reported here for transparency of the full study procedure; data 145 will be presented elsewhere. 146

Hyperphagia questionnaire: The Hyperphagia Questionnaire (26) was used to measure hyperphagic
eating behaviour across three subscales (drive, behaviour, and severity). Higher scores reflect a
greater frequency and severity of food-related preoccupations and hyperphagic associated
problems. To calculate a total hyperphagia score, the three subscales were summed. A modified,
self-report version of the Hyperphagia Questionnaire was created for patients over 18 years old for
this study.

153

Eating Behaviour questionnaire: The Child Eating Behaviour Questionnaire (CEBQ)(27) was used to measure appetitive traits associated with obesity risk in childhood. Participants over 18 years old completed the corresponding Adult Eating Behaviour Questionnaire (AEBQ) (42). This study also took an average of the three food approach traits and the four food avoidance traits to create a composite food approach score and a composite food avoidance score.

159

Quality of Life (QoL): QoL was assessed using the Minneapolis-Manchester Quality of Life Survey of
 Health for Children and Young people (MMQL)(43). A parent of patients under 18 years completed

the parallel parent version of the MMQL (44).

163

| 164 | Ad libitum meal: The ad libitum lunch consisted of 14 vegetarian, hot and cold foods and two |
|-----|---|
| 165 | beverages served in excess and laid out in a standardised fashion. The total energy in the meal was |
| 166 | 30,049KJ (37, 49, 11% of energy from fat, carbohydrate, and protein, respectively (Table 1). Each |
| 167 | item was covertly weighed to the nearest gram by the investigator before and after the lunch. |
| 168 | Patients remained in a room alone for 30 minutes and were asked to eat to appetite. |
| 169 | |
| 170 | Acceptability questionnaire(s): Age-appropriate questionnaires (10 years old and under, 11-15 years |
| 171 | old or 16 years and over) were designed specifically for this study to assess patient tolerability of the |
| 172 | number and nature of study measures. Questions were worded to suit the participant's age group |
| 173 | and therefore not all questions were asked of all participants. Additionally, a parent/carer of the |
| 174 | patient completed the parent/carer acceptability questionnaire. Questions were presented on a five- |
| 175 | point rating scale; for patients \leq 10 years and for those 11-15 years old, the five-point rating scale |
| 176 | included different faces from a red sad face to a green happy face. The five-point rating scale for |
| 177 | patients ≥16 years and parents ranged from 1 = not at all to 5 = extremely. Some questions required |
| 178 | a yes or no response and included sections where the individual could comment freely. |
| 179 | |

180 Procedure

181 Each participant was tested individually over the course of one morning at the Clinical Research

182 Facility. The procedure, shown in Figure 1, for the control group was identical to that for patients

183 with craniopharyngioma, except that the control group did not have an MRI scan or blood tests.


184

185 After an overnight fast of at least eight hours, participants received the above measures in the

186 following order: body composition, resting metabolic rate, OGTT including MRI, appetite ratings and

187 blood sampling), eating behaviour and QoL questionnaires, ad libitum lunch, and acceptability

188 questionnaire. Participants were given a shopping voucher to thank them for their time and effort.



191

192

193 Data processing and statistical analysis

194 The feasibility outcomes of the study were operationalised as follows: (i) patient data on key 195 measures, including Paris grading of tumour, and pre- and post-op BMI; (ii) recruitment (no. of 196 participants recruited and % of target sample); (iii) acceptability of the measures (scores of between 197 1 to 5 and comments) by participants and their parent/carer, and tolerance of the protocol (no. of 198 participants who completed the full data set); (iv) preliminary data on the eating behaviour 199 measures described above were summarized using medians (IQR) and frequencies where 200 appropriate.

201

A priori, we decided to report effect sizes, due to concerns about null-hypothesis significance testing 202 203 in small sample sizes and because p values do not indicate the magnitude of any reported effects 204 [31–33]. Cliff's delta was chosen as it has no assumptions on the underlying distribution and 205 performs well for small sample sizes (n>10; (45)). Cliff's delta and associated 95% confidence 206 intervals were calculated using an available Excel macro (45). The macro notes that for the variables 207 with a sample size of less than 10, the accurate estimation of the 95% confidence intervals is 208 compromised. Descriptors of magnitude of effect size were 0.11 for small effect size, 0.28 for 209 medium effect size and 0.43 for large effect size (45). For correlations, Kendall's tau was used, and

| 210 | the following descriptors were applied for the magnitude of the correlation coefficient with $r = 0.10$ |
|-----|---|
| 211 | for small effect size, r = 0.30 for medium effect size and r = 0.50 for large effect size. Data was |
| 212 | analyzed using SPSS version 24. |

213

214 **Results**

- 215 *Participant characteristics (objective 1)*
- 216 Comprehensive searching of medical records, including the archives, allowed the full clinical
- 217 characterisation of the 11 patients with craniopharyngioma to be presented in Table 2. Age at
- 218 diagnosis ranged from 5 to 15 years, with surgical techniques used to treat the craniopharyngioma
- ranging from debulking, cyst aspiration and transsphenoidal resection. 9/11 patients had also
- 220 received radiotherapy. Post-operatively, all patients had adrenocorticotropin hormone (ACTH) and
- growth hormone deficiencies, 10/11 had thyroid dysfunction and 6/11 had diabetes insipidus. There
- was wide variation in BMI SDS at 12 months post-op from underweight to obese categorisations, and
- the extent of hypothalamic damage varied across the Paris grading (Table 2).
- 224

225 *Recruitment (objective 2)*

226 Eleven patients with craniopharyngioma were recruited over the period of two years from January

227 2019 until December 2020 (Figure 2). This time period included the first COVID-19 lockdown.

Healthy-weight, matched control participants were recruited from October 2020 to October 2021. A

target of 20 patients with craniopharyngioma was set and 55% of this target was reached during the


study period with a marked reduction in the second year due to COVID-19 lockdown. 58% of those

invited to take part did go on to participate (Figure 2). Reasons for not participating included patient

- 232 illness, family health problems, and unwillingness to travel.
- 233
- 234
- 235
- 236
- 237

238

239



268 Overall, participants found the various aspects of the study highly acceptable and well tolerated.

269 Table 3 reports missing data, acceptability, and tolerability of each measure. The number of patients

and controls who completed each of the measures (between 80-100%) is reported in Table 4.

271

272 Preliminary data with matched controls (objective 4)

As intended, the groups were well-matched on sex, pubertal stage, and age (Table 4).

274 Body composition, energy intake and energy expenditure: Patients had a higher BMI SDS, and

absolute and percentage fat mass compared to controls with a large effect size for each measure. No

276 difference was found between groups in RMR (Table 4). Total energy intake at the *ad libitum test*

277 meal did not differ between groups. When macronutrient intake was expressed as a percentage of

total energy, patients consumed more carbohydrate and fat, and less protein than controls.

279

280 Eating behaviour questionnaires: There was greater hyperphagia in the patients compared to 281 controls, with the largest effect size for the hyperphagia severity subscale (d=0.7; Table 4). More 282 time spent talking or engaging with food and a greater extent to which food interfered with daily 283 functioning was reported in patients. Results from the A/CEBQ showed greater food approach 284 behaviours (such as enjoyment and responsiveness to food and emotional overeating) in patients 285 with a medium to large effect size (Table 4). By contrast, greater food avoidance behaviours, such as 286 slowness in eating, satiety responsiveness and food fussiness, were reported for controls, with 287 medium to large effect sizes (Table 4).

288

Quality of life (QoL): QoL of participants overall was lower in patients than controls, both as reported by the young people with a medium effect size, and by their parent/carer with a large effect size (Table 4). Lower QoL was reported by parents of patients compared to their children (d = 0.26), whereas young people in the control group rated their QoL lower than their parents (d = -0.22). Patients reported that their health restricted their activities ('physical functioning' subscale) to a greater extent than controls, whereas the largest differences in parents/carer ratings between groups were found for the physical and social functioning (having close friends with similar interests)

and functioning at school (concentration and difficulty with schoolwork) subscales, with lower QoL

- 297 on these subscales for the patients.
- 298

299 Relationship between eating behaviour measures and BMI-SDS

300 A positive correlation between food approach behaviours and BMISDS was found with a large effect

301 size in patients but not matched controls (Table 5). A positive correlation was found between

302 hyperphagia total score and BMISDS in patients, with a much weaker relationship in controls.

303 Conversely, a negative correlation of medium effect size was seen between food avoidance

behaviours and BMISDS in patients, with only a weak relationship in controls.

305

306 Relationship between QoL, eating behaviour and BMISDS

307 Only weak evidence was found for negative correlations between participant-reported QoL total 308 score and BMISDS (patients = -0.20; controls = 0.13, small effect sizes) and parent-reported QoL total 309 score and participants BMISDS (patients = -0.25, medium effect size; controls = -0.18, small effect 310 size). In patients, there was little evidence for a relationship between their self-reported QoL scores 311 and energy intake or expenditure or eating behaviour measures (small effect sizes only) (Table 6). For parent/carer QoL measure, relationships of medium effect size were found with food avoidance 312 313 and hyperphagia scores, whereby greater food avoidance behaviours were positively correlated, and hyperphagia scores negatively correlated, with QoL. 314

315

316 **Discussion**

This study has demonstrated it is feasible and acceptable to conduct multi-component, eating behaviour research in young people with craniopharyngioma. While recruitment of adequate patient numbers from two sites was challenging, 58% of those invited participated. Overall, the included measures were deemed highly tolerable by participants and their parents and have provided preliminary data to begin to investigate in one cohort, the consequences of hypothalamic damage on energy intake, energy expenditure and eating behaviour, and the impact these may have on quality of life.

324

325 Feasibility of research into eating behaviour and obesity in young people with craniopharyngioma

326 Previous research has indicated that recruitment can be challenging in studies of craniopharyngioma 327 due to the complexity of the condition (46). Indeed, considering the heterogeneity of disease and 328 treatment complications following craniopharyngioma (47), it is unsurprising that 10 of the 21 329 patients initially identified did not align with the study criteria. This included those with severe visual 330 problems who could not be included due to the requirements of completing the task in the MRI 331 scanner. Other reasons for not participating were given by invited families, such as difficulty of scheduling clinical sessions at the same time as the research session, and anxiety surrounding having 332 333 blood taken were noted. Moreover, the COVID-19 pandemic suspended testing from March-October 334 2020. Future studies should recruit from several specialist centres to obtain sufficient patient 335 numbers and should allow access to participate in different aspects of the study if not all criteria are 336 met.

337

Participants broadly found the protocol both tolerable and acceptable. Aspects of the OGTT, 338 339 including the glucose drink, blood tests, and missing breakfast to be fasted were the least tolerable 340 components of the protocol. The meal elicited the most comments with several participants 341 reporting they enjoyed it, others asking for more choice, with another commenting that the 342 environment felt artificial. The experience of taking part was valued by young people and their 343 parents alike, with many commenting on the importance, yet lack of understanding, of eating 344 behaviour for those with craniopharyngioma. Several parents reported changes and difficulties with their child's eating and could also see the wider benefits of taking part. 345

346

347 Preliminary data comparing those with and without craniopharyngioma

348 Analysis of the preliminary data was conducted to inform a larger, multi-centre trial to assess

interventions designed to improve eating behaviour in young people with hypothalamic obesity. To

350 the authors' knowledge, only one study has conducted an *ad libitum* meal to measure dietary intake

in craniopharyngioma patients (17). However, in the current small, feasibility study, only a weak

- 352 relationship between total energy intake and BMISDS was found in patients with
- 353 craniopharyngioma, suggesting that it is difficult to assess whether the amount of food consumed is
- a primary driver of obesity for these patients using an acute measure from a standard meal alone.

355

By contrast, questionnaire measures of eating behaviour consider habitual eating traits over a longer
 period (27, 42). Preliminary evidence was found for greater food approach behaviours, including

hyperphagic behaviours of greater severity (26), in patients with craniopharyngioma compared to 358 359 sex, pubertal stage and age matched controls. Shoemaker and colleagues (17) also found similar 360 levels of hyperphagia and variability in scores across patients using the Hyperphagia questionnaire, 361 with high levels of enjoyment of food, like the current study. Together, these findings suggests that 362 young people with craniopharyngioma experience enjoyment from their food, but in some cases, 363 this heightened food responsivity could lead to problematic behaviours, such as stealing food or anger outbursts if access to food is removed. Moreover, both food approach and hyperphagia were 364 365 positively correlated with BMISDS with a medium to strong effect size, suggesting that the greater drive patients with craniopharyngioma have to engage in food approach and consumption 366 behaviours, the higher level of BMISDS. Moderating hyperphagia scores, therefore, could be an 367 368 informative primary outcome for a future trial. A power calculation (using G*Power, assuming 80% power to detect a difference between groups) based on the effect size from this study (d=1.0) 369 370 suggests that a minimum of 27 participants would be required in each group. These numbers, 371 together with the high patient acceptability of the questionnaire measures, suggests hyperphagia score change (26), could be a feasible outcome for a future trial which would allow the exploration 372

of other confounding factors, such as hypothalamic damage and history of surgery and radiotherapy.

374

375 For there to be a clear patient benefit, it is also important to assess the impact on QoL. Interestingly, 376 QoL as rated by the parents of young people in this study was found to be related to these same 377 hyperphagic eating behaviours with a medium effect size; that is, QoL was rated as lower for those 378 young people with greater hyperphagic and food approach tendencies. Moreover, QoL was rated 379 higher by parents of those who engaged in more food avoidance behaviours. Yet, this was not the 380 case for QoL as rated by the young people themselves. One could speculate, that as they experience 381 enjoyment from food, they do not always make the link between their eating and QoL, especially as 382 in this sample, there was only a weak relationship between BMISDS and QoL. This is an interesting 383 concept to explore further in future research.

384

When considering which other measures to include in a future trial, the findings from this study suggest that the body composition measures show clear, informative differences between patients and controls and were broadly feasible and acceptable to participants. Measurement of energy expenditure was more challenging in this young patient group. While no difference in resting metabolic rate was found between groups, contrary to previous studies (29-31), discrepancies between our findings and the previous work could be due to differing levels of BMISDS or

391 hypothalamic damage and a smaller sample size in our feasibility study or the characteristics of the 392 comparison groups (healthy weight or obese). This point highlights the inconsistencies of research 393 into eating behaviour and the development of obesity within this patient group, both in terms of 394 study design and findings to date, and provides the impetus to design larger, multi-centre trials with 395 appropriate control groups within international networks of collaborators to further this field. The 396 MRI and OGTT measures were also well tolerated, and while challenging to collect complete 397 datasets, should be considered for future research designed to investigate the neural and 398 physiological mechanisms underlying the development of obesity, and could be applied to further 399 understand mechanisms of action of new drug therapies, such as GLP1 agonists, in this patient group 400 (17). Full characterization of the patients is important in any future trial to ascertain whether 401 behavioural and pharmacological interventions are differentially effective based on key factors, such 402 as hypothalamic damage, development of obesity post-surgery and endocrine abnormalities.

403

404 Limitations

405 There are missing data from several of the included measures; specifically, there were some user-406 related problems with the energy expenditure and body composition equipment, and difficulties in 407 the cannulation of one of the young patients with obesity. However, this feasibility study has 408 allowed the identification and response to potential difficulties of conducting this type of in-depth 409 clinical study to take forward. It is important to note when considering the above findings that the 410 control group reported in this paper was purposefully not matched on BMISDS for this study. This 411 design choice has precedence in the literature (e.g. 30). The original design of the study was to 412 recruit two control participants for each patient, one of healthy weight and one in the obese 413 category; however, it proved very challenging to recruit young people with obesity to take part 414 during the period of this research project, which coincided with the COVID-19 pandemic. All those 415 who volunteered and matched a patient on sex, pubertal stage, and age, were of a healthy weight. 416 However, the larger study, including MRI and OGTT measures, has a historical control group, 417 comprising young people living with and without obesity, who took part in a previous MRI study 418 investigating food-cue reactivity around a OGTT (41). The overlapping measures from these datasets, 419 including OGTT results and food-cue reactivity during functional neuroimaging, will be presented in a 420 future paper.

421

422 Conclusion

423 The findings from this study suggest that the food approach behaviours, including food 424 responsiveness and enjoyment of food, and for some patients, more severe instances of hyperphagic 425 behaviours, show the strongest link with BMISDS. Future research should investigate how these 426 specific behaviours may change over time, from pre to post surgery, depending on factors such as 427 hypothalamic damage. Food approach behaviours may be useful targets for interventions to help 428 patients with their eating; food-related, response inhibition training for example, has been shown to 429 reduce consumption of high energy dense foods in adults and children (48, 49). Conversely, 430 encouraging food avoidance behaviours, such as slowness in eating or responsiveness to satiety, 431 may also serve to reduce food intake and improve health-related quality of life. It is important for 432 future research, therefore, to ensure that the design of the study does allow the key questions to be 433 addressed and does not exclude the participants with relevant symptoms. A key strength of this 434 work is including the patient's and their parent's voice early in the research pathway; this area of

- 435 research is important to patient and their families, and they are strongly motivated to support
- 436 research which aligns closely with their key concerns.

438 Statements

439 Acknowledgement

- 440 We thank the young people and parents for participating in this study. We also thank Aileen Wilson
- 441 and the staff at CRICBristol/Clinical Research Facility.

442 Statement of Ethics

- 443 <u>Study approval statement</u>: This study protocol was reviewed and approved by the South West -
- 444 Frenchay Research Ethics Committee, approval number 18/SW/0235 (Nov 2018).
- 445 <u>Consent to participate statement</u>: In accordance with HRA and General Medical Council guidance,
- 446 written informed consent was obtained from participants if aged 16 years or over, or by their parent
- if 15 years or younger. Participants 15 years or younger provided assent to participate. This consent
- 448 process is detailed in the methods section and was approved by the above Research Ethics
- 449 Committee.

450 **Conflict of Interest Statement**

451 The authors have no conflicts of interest to declare.

452 Funding Sources

- 453 This study was funded through the University Hospitals Bristol and Weston NHS Trust Research
- 454 Capability Funding scheme, and supported by the NIHR Biomedical Research Centre, Nutrition
- 455 theme. The views expressed in this publication are those of the authors and not necessarily those of
- 456 the NHS, the National Institute for Health Research or the Department of Health and Social Care.

457 Author Contributions

EH, FL, LC, KN, and JHS designed the study; EH, KN, FL, RLE, KH, SS, HB, NN, RE, TTM collected the
data; EH, FL, RLE, SS, HB, NN analysed the data; EH wrote the first draft of the paper; all authors
commented and contributed to the final manuscript.

461 Data Availability Statement

- 462 All data generated or analyzed during this study are included in this article. Further enquiries can be463 directed to the corresponding author.
- 464
- 465
- 466

467

Figure Legends

- Fig. 1. Study procedure
- Fig. 2. Participant flow chart

References

| 469 | 1. Muller HL. Craniopharyngioma. Endocr Rev. 2014;35(3):513-43. |
|-----|---|
| 470 | 2. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive |
| 471 | epidemiology of craniopharyngioma. Journal of neurosurgery. 1998;84(4):547-51. |
| 472 | 3. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and |
| 473 | central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14 |
| 474 | Suppl 5:v1-49. |
| 475 | 4. Muller HL. Consequences of craniopharyngioma surgery in children. J Clin Endocrinol Metab. |
| 476 | 2011;96(7):1981-91. |
| 477 | 5. Muller HL. Risk-adapted, long-term management in childhood-onset craniopharyngioma. |
| 478 | Pituitary. 2017;20(2):267-81. |
| 479 | 6. Wijnen M, Olsson DS, van den Heuvel-Eibrink MM, Wallenius V, Janssen JA, Delhanty PJ, et |
| 480 | al. Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a |
| 481 | matched case-control study with 2 years of follow-up. Int J Obes (Lond). 2017;41(2):210-6. |
| 482 | 7. Roth CL. Hypothalamic Obesity in Craniopharyngioma Patients: Disturbed Energy |
| 483 | Homeostasis Related to Extent of Hypothalamic Damage and Its Implication for Obesity Intervention. |
| 484 | J. 2015;4(9):1774-97. |
| 485 | 8. Sorva R. Children with craniopharyngioma. Early growth failure and rapid postoperative |
| 486 | weight gain. Acta Paediatr Scand. 1988;77(4):587-92. |
| 487 | 9. Muller HL. Childhood craniopharyngioma. Recent advances in diagnosis, treatment and |
| 488 | follow-up. Horm Res. 2008;69(4):193-202. |
| 489 | 10. Pereira AM, Schmid EM, Schutte PJ, Voormolen JHC, Biermasz NR, Van Thiel SW, et al. High |
| 490 | prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for |
| 491 | craniopharyngioma. Clin Endocrinol (Oxf). 2005;62(2):197-204. |
| 492 | 11. Olsson DS, Andersson E, Bryngelsson IL, Nilsson AG, Johannsson G. Excess mortality and |
| 493 | morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a |
| 494 | population-based study in Sweden. J Clin Endocrinol Metab. 2015;100(2):467-74. |
| 495 | 12. Srinivasan S, Ogle GD, Garnett SP, Briody JN, Lee JW, Cowell CT. Features of the metabolic |
| 496 | syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab. 2004;89(1):81-6. |
| 497 | 13. Holmer H, Ekman B, Bjork J, Nordstom CH, Popovic V, Siversson A, et al. Hypothalamic |
| 498 | involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long- |
| 499 | term GH therapy. Eur. 2009;161(5):671-9. |
| 500 | 14. Erfurth EM. Endocrine aspects and sequel in patients with craniopharyngioma. Journal of |
| 501 | Pediatric Endocrinology and Metabolism. 2015;28(1-2):19-26. |
| 502 | 15. Shah E, Lodh R, Siddell P, Morrall MC. Interventions for managing weight change following |
| 503 | paediatric acquired brain injury: a systematic review. Dev Med Child Neurol. 2016;58(10):1004-8. |
| 504 | 16. Hamilton JK, Conwell LS, Syme C, Ahmet A, Jeffery A, Daneman D. Hypothalamic Obesity |
| 505 | following Craniopharyngioma Surgery: Results of a Pilot Trial of Combined Diazoxide and Metformin |
| 506 | Therapy. Int J Pediatr Endocrinol. 2011;2011:417949. |
| 507 | 17. Shoemaker AH, Silver HJ, Buchowski M, Slaughter JC, Yanovski JA, Elfers C, et al. Energy |
| 508 | balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor |
| 509 | agonist. Int J Obes (Lond). 2022;46(3):623-9. |
| 510 | 18. Roth CL, Eslamy H, Werny D, Elfers C, Shaffer ML, Pihoker C, et al. Semiquantitative analysis |
| 511 | of hypothalamic damage on MRI predicts risk for hypothalamic obesity. Obesity (Silver Spring). |
| 512 | 2015;23(6):1226-33. |
| | |

medRxiv preprint doi: https://doi.org/10.1101/2023.01.10.23284332; this version posted January 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

513 19. Nogueira MC, Berbel Junior AS, Koenigkam-Santos M, Moreira AC, Nonino CB, de Castro M. 514 Nutritional and endocrinologic evaluation of patients with craniopharyngioma. Clin Nutr ESPEN. 2015;10(6):e213-e8. 515 516 20. Hsu EA, Miller JL, Perez FA, Roth CL. Oxytocin and Naltrexone Successfully Treat 517 Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection. J Clin Endocrinol Metab. 518 2018;103(2):370-5. 519 21. Pierre-Kahn A, Recassens C, Pinto G, Thalassinos C, Chokron S, Soubervielle JC, et al. Social 520 and psycho-intellectual outcome following radical removal of craniopharyngiomas in childhood. A 521 prospective series. Childs Nerv Syst. 2005;21(8-9):817-24. 522 22. Skorzewska A, Lal S, Waserman J, Guyda H. Abnormal food-seeking behavior after surgery 523 for craniopharyngioma. Neuropsychobiology. 1989;21(1):17-20. 524 Harz KJ, Muller HL, Waldeck E, Pudel V, Roth C. Obesity in patients with craniopharyngioma: 23. 525 assessment of food intake and movement counts indicating physical activity. J Clin Endocrinol 526 Metab. 2003;88(11):5227-31. 527 24. Daubenbuchel AM, Ozyurt J, Boekhoff S, Warmuth-Metz M, Eveslage M, Muller HL. Eating 528 behaviour and oxytocin in patients with childhood-onset craniopharyngioma and different grades of 529 hypothalamic involvement. Pediatr Obes. 2019;14(9):e12527. 530 25. Roth CL, Aylward E, Liang O, Kleinhans NM, Pauley G, Schur EA. Functional neuroimaging in 531 craniopharyngioma: a useful tool to better understand hypothalamic obesity? Obes Facts. 532 2012;5(2):243-53. 533 26. Dykens EM, Maxwell MA, Pantino E, Kossler R, Roof E. Assessment of hyperphagia in Prader-534 Willi syndrome. Obesity (Silver Spring). 2007;15(7):1816-26. 535 27. Wardle J, Guthrie CA, Sanderson S, Rapoport L. Development of the Children's Eating 536 Behaviour Questionnaire. J Child Psychol Psychiatry. 2001;42(7):963-70. 537 Hinton EC, Elsworth RL, Naeem N, Szymkowiak SB, Perry R, Candler TP, et al. Exploring eating 28. 538 behavior and psychological mechanisms associated with obesity in patients with craniopharyngioma: 539 a scoping review protocol. JBI Evid Synth. 2022;20(1):284-96. 540 29. Bomer I, Saure C, Caminiti C, Ramos JG, Zuccaro G, Brea M, et al. Comparison of energy 541 expenditure, body composition, metabolic disorders, and energy intake between obese children 542 with a history of craniopharyngioma and children with multifactorial obesity. J Pediatr Endocrinol 543 Metab. 2015;28(11-12):1305-12. 544 Holmer H, Pozarek G, Wirfalt E, Popovic V, Ekman B, Bjork J, et al. Reduced energy 30. 545 expenditure and impaired feeding-related signals but not high energy intake reinforces 546 hypothalamic obesity in adults with childhood onset craniopharyngioma. J Clin Endocrinol Metab. 547 2010;95(12):5395-402. 548 Kim RJ, Shah R, Tershakovec AM, Zemel BS, Sutton LN, Grimberg A, et al. Energy expenditure 31. 549 in obesity associated with craniopharyngioma. Childs Nerv Syst. 2010;26(7):913-7. 550 van Iersel L, Brokke KE, Adan RAH, Bulthuis LCM, van den Akker ELT, van Santen HM. 32. 551 Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following 552 Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review. Endocr Rev. 553 2019;40(1):193-235. 554 33. Pinto G, Bussieres L, Recasens C, Souberbielle JC, Zerah M, Brauner R. Hormonal factors 555 influencing weight and growth pattern in craniopharyngioma. Horm Res. 2000;53(4):163-9. 556 Goldstone AP, Patterson M, Kalingag N, Ghatei MA, Brynes AE, Bloom SR, et al. Fasting and 34. 557 postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, 558 and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to 559 craniopharyngioma. J Clin Endocrinol Metab. 2005;90(5):2681-90. Roth CL, Gebhardt U, Muller HL. Appetite-regulating hormone changes in patients with 560 35. 561 craniopharyngioma. Obesity (Silver Spring). 2011;19(1):36-42.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.10.23284332; this version posted January 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

56236.Heinks K, Boekhoff S, Hoffmann A, Warmuth-Metz M, Eveslage M, Peng J, et al. Quality of563life and growth after childhood craniopharyngioma: results of the multinational trial

564 KRANIOPHARYNGEOM 2007. Endocrine. 2018;59(2):364-72.

565 37. Kendall-Taylor P, Jonsson PJ, Abs R, Erfurth EM, Koltowska-Haggstrom M, Price DA, et al. The 566 clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset 567 cranionbary gioma compared with adult onset cranionbary gioma. Eur. 2005;152(4):557-67

567 craniopharyngioma compared with adult-onset craniopharyngioma. Eur. 2005;152(4):557-67.
568 38. Yano S, Kudo M, Hide T, Shinojima N, Makino K, Nakamura H, et al. Quality of Life and

Sola Sola Faillo S, Kudo M, Hue F, Shinojina N, Makino K, Nakanula H, et al. Quality of Life and
 Clinical Features of Long-Term Survivors Surgically Treated for Pediatric Craniopharyngioma. World
 Neurosurg. 2016;85:153-62.

39. Poretti A, Grotzer MA, Ribi K, Schonle E, Boltshauser E. Outcome of craniopharyngioma in
children: Long-term complications and quality of life. Developmental Medicine and Child Neurology.
2004;46(4):220-9.

40. Cole TJ, Green PJ. Smoothing reference centile curves: The LMS method and penalized
likelihood. Statistics in Medicine. 1992;11:1305-19.

Hinton EC, Birch LA, Barton J, Holly JMP, Biernacka KM, Leary SD, et al. Using neuroimaging
to investigate the impact of Mandolean(R) training in young people with obesity: a pilot randomised
controlled trial. BMC Pediatr. 2018;18(1):366.

579 42. Hunot C, Fildes A, Croker H, Llewellyn CH, Wardle J, Beeken RJ. Appetitive traits and 580 relationships with BMI in adults: Development of the Adult Eating Behaviour Questionnaire.

581 Appetite. 2016;105:356-63.

Hutchings HA, Upton P, Cheung WY, Maddocks A, Eiser C, Williams JG, et al. Adaptation of
the Manchester-Minneapolis Quality of Life instrument for use in the UK population. Arch Dis Child.
2007;92(10):855-60.

Hutchings HA, Upton P, Cheung WY, Maddocks A, Eiser C, Williams JG, et al. Development of
a parent version of the Manchester-Minneapolis quality of life survey for use by parents and carers
of UK children: MMQL-UK (PF). Health Qual Life Outcomes. 2008;6:19.

588 45. Goedhart J. Calculation of a distribution free estimate of effect size and confidence intervals 589 using VBA/excel. bioRxiv. 2016.

46. Pedreira CC, Stargatt R, Maroulis H, Rosenfeld J, Maixner W, Warne GL, et al. Health related
quality of life and psychological outcome in patients treated for craniopharyngioma in childhood. J
Pediatr Endocrinol Metab. 2006;19(1):15-24.

47. Lo AC, Howard AF, Nichol A, Sidhu K, Abdulsatar F, Hasan H, et al. Long-term outcomes and
complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience.
Int J Radiat Oncol Biol Phys. 2014;88(5):1011-8.

Lawrence NS, O'Sullivan J, Parslow D, Javaid M, Adams RC, Chambers CD, et al. Training
response inhibition to food is associated with weight loss and reduced energy intake. Appetite.
2015;95:17-28.

599 49. Porter L, Gillison FB, Wright KA, Verbruggen F, Lawrence NS. Exploring Strategies to Optimise

600 the Impact of Food-Specific Inhibition Training on Children's Food Choices. Front Psychol.

601 2021;12:653610.

602 Table 1 - Energy content and macronutrient composition of the ad libitum meal

| Item | Amount (g) | Energy KJ | Fat | СНО | Protein |
|-------------------|------------|-----------|------|------|---------|
| Macaroni cheese | 400 | 2733 | 29 | 66 | 30 |
| Wholemeal bread | 241 | 2388 | 8 | 87 | 17 |
| White bread | 208 | 2107 | 5 | 95 | 17 |
| Flora | 70 | 1170 | 32 | 0 | 0 |
| Cheese | 240 | 4140 | 84 | 1 | 61 |
| Humus | 115 | 1323 | 25 | 12 | 8 |
| red capsicum | 68 | 61 | 0 | 3 | 1 |
| Tomato | 127 | 77 | 0 | 4 | 1 |
| Fruit loaf | 500 | 6355 | 15 | 291 | 41 |
| OJ | 1000 | 1760 | 5 | 86 | 6 |
| Mandarin | 560 | 969 | 1 | 54 | 4 |
| Мауо | 38 | 1127 | 30 | 0 | 0 |
| Choc Chip cookies | 230 | 4743 | 55 | 143 | 13 |
| Walkers crisps | 50 | 1097 | 16 | 26 | 3 |
| | Total | 30049 | 304 | 868 | 201 |
| | %E | | 37.4 | 49.1 | 11.4 |

| Participa nt no. | Sex | Age range at diagno | Surgery | Radio- therapy received (yes/no) | Paris g | grading | BMI SDS | 5 | Diab insip | | Thyroi dysfur | | ACTH defic | l iency | GH deficie | ency |
|---------------------|-----|------------------------------|----------------------------|---|------------|-------------|---------|-------|---------------|---------|------------------|---------|---------------|------------|---------------|---------|
| | | sis (years) | | | Pre- op | Post- op | Pre-op | 12m | Pre -op | 12 m | Pre- op | 12 m | Pre -op | 12 m | Pre- op | 12 m |
| 1 | F | 6-10 | Debulking | Yes | 2 | 1 | 3.20 | 3.4 | x | у | У | У | У | у | x | у |
| 2 | М | 6-10 | Debulking | Yes | 2 | 2 | 2.93 | 2.99 | x | х | х | У | x | У | х | у |
| 3 | М | 6-10 | VAD | No | 1 | 1 | -0.28 | -0.79 | x | х | У | У | У | у | у | У |
| 4 | М | 11-15 | Aspiration of cyst, VAD | Yes | 2 | 2 | -0.38 | -1.08 | x | x | x | У | У | У | x | У |
| 5 | F | 0-5 | Debulking | Yes | 2 | 2 | 1.43 | 3.43 | x | У | x | У | x | у | x | у |
| 6 | F | 6-10 | TSR | Yes | | 0 | 0.09 | 0.94 | x | У | у | У | У | у | x | у |
| 7 | F | 11-15 | TSR | Yes | 0 | 0 | 0.17 | 0.72 | x | У | у | У | У | у | x | у |
| 8 | М | 11-15 | Aspiration of cyst, | Yes | 2 | 2 | 1.60 | 0.10 | x | x | x | x | x | у | x | У |
| 9 | М | 16-20 | TSR | No | 0 | 0 | -2.42 | -0.76 | У | у | У | У | У | У | у | У |
| 10 | F | 11-15 | Debulking, VAD | Yes | 1 | 2 | -0.84 | 0.61 | x | х | У | У | у | у | х | У |

604Table 2 - Clinical characterisation of the patients with craniopharyngioma

| 11 | М | 6-10 | Aspiration of cyst | Yes | 2 | 2 | 0.18 | 1.34 | х | У | х | У | х | У | x | У |
|---------|------------|--------|--------------------|-----|---|---|--------|--------|-----|-----|-----|-----|-----|-----|-----|-----|
| Overall | F: | | Debulking: 4/11 | | | | | | | | | | | | | |
| (n=11) | 5/11 | | Cyst aspiration: | | | | | | 1 | 6 | 6 | 10 | 7 | 11 | 2 | 11 |
| | M: 6/11 | | 4/11 | | | | | | /11 | /11 | /11 | /11 | /11 | /11 | /11 | /11 |
| Mean | | 10.8 | TSR: 3/11 | | | | 0.52 | 0.99 | | | | | | | | |
| (S.D) | | (3.49) | | | | | (1.65) | (1.66) | | | | | | | | |

605 S.D = standard deviation; F=female; M = male; VAD = ventricular access device; TSR = transphenoidal resection; Pre-op = Pre-operatively; Post-op = post-

606 operatively; 12m = 12 months post-operatively; BMI SDS = body mass index standard deviation score; ACTH = adrenocorticotropin hormone; GH = growth

607 hormone; y = yes, present.

608

610 Table 3 – Feasibility and acceptability of included measures

| Measure | Data issues | Acceptability rating (median, 95% C.I.) | Patient or Parent comments / notes (age range in brackets) |
|--------------------------------|---|---|--|
| Body composition | n=4 missing for the trunk measurement due to data recording issues. | Patient = 5, 95% Cl: 4-5; Control = 5, 95% Cl: 4-5 | <i>"I also found it interesting to learn about the children's muscle mass"</i> (parent of 11-15y, M) |
| Resting metabolic rate | n=3 not possible to collect data due to technical issues with the equipment. Some found lying still for 20 minutes to collect the data difficult. | Patient = 5, 95% Cl: 4-5; Control = 4.5, 95% Cl: 3-5 | "it was wierd but it was fine" (11-15yr, F) |
| Oral glucose tolerance test | n=1 not possible to cannulate | Glucose drink: Patient = 3, 95% Cl: 2-5; Control = 4, 95% Cl: 2-4 Bloods: Patient = 4, 95% Cl: 4-5 | <i>"it was gloopy, too sweet and not nice"</i> (11-15yr, F) <i>"Didn't taste very nice"</i> (11-15yr, M) <i>"obviously I didn't want to do it, but it didn't hurt so it was fine"</i> (11-15yr, F) <i>"it will hopefully negate the need for my next blood test which is a bonus!"</i> (21-25yr, F) |
| MRI | n=2 data not collected due to bioplate and suspected surgical clips | Bloods: Patient = 4, 95% CI: 3-5 | "the first one was uncompfy but the other one was fine" (11-15yr, F) |
| Questionnaires | No issues | Patient = 5, 95% CI: 4-5; Control = 4, 95% CI: 4-5 | If the participant was 18 years or older, they were not required to have a parent or carer present in order to complete the acceptability or QoL parent/carer data |
| Ad libitum lunch | n=1 control participant reported food allergies after testing had started so their data were excluded as it was incomplete | Patient = 5, 95% CI: 4-5; Control = 5, 95% CI: 4-5 | "more choice" (11-15yr, M) "There was a wide range however the eating environment felt artificial to me" (21-25yr, M) "I really liked the oranges" (11-15yr, M) |

| | | | "Great food" (11-15yr, M) |
|---|-----------|--|--|
| How <i>interesting</i> did you find the project overall? | No issues | Patient = 4, 95% CI: 3-5; Control = 4, 95% CI: 4-5 | "I have always been intrigued around my eating habits since my op so it has really interested me being asked to do this research project" (16-20yr, F) |
| Fasting overnight | No issues | Patient = 4, 95% CI: 3-5; Control = 4, 95% CI: 3-5 | "I got very hungry and it was hard to have a different routine" (11-15yr, F) "anticipation worse than actually missing it*" (11-154yr, M) *breakfast |
| Travelling and staying overnight | No issues | Patient = 3, 95% Cl: 3-5; patients only. | |
| How important do you think it is to investigate how eating behaviour in childhood craniopharyngioma? | No issues | Free text comments only | "it is easy to focus on the endocrine/ surgical side of things without investigating how QoL can be improved. Eating behaviour is something which can have a wide impact, not only on someone's health but also on their mental and social wellbeing hence the need for such studies" (21-25yr, F) "Very important. We're struggling with participant's diet and appetite." (parent of 6-10yr, F) "It is clearly very important, there is a link between craniopharyngioma and obesity, yet it appears no real explanation as to why this is." (parent of 6-10yr, M) |
| Reported changes in eating | No issues | Free text comments only | " eating habits have definitely changed since his diagnosis. He clearly talks more about food and always wants to know what's for tea!" (parent of 6-10yr, M) |
| Benefits of taking part | No issues | Free text comments only | "the care has received throughout her childhood and adult life will have benefitted from research projects in the past. To be involved in further research will hopefully help future |

| | sufferers of craniopharyngioma." |
|--|----------------------------------|
| | (parent of 21-25yr, F). |
| | |

611

Table 4 – Comparison of the craniopharyngioma patient and control groups. 612

| Measure | Patients with craniopharyngi | oma | Matched-contro participants | ol | Effect size |
|-----------------------------------|------------------------------|-----|------------------------------------|----|------------------------------|
| | Median (IQR) or frequency | N | median/IQR or frequency | N | Cliff's delta (95% C.I.s) |
| Demographic data | | | | | |
| Sex (M/F) | 6/5 | 11 | 6/5 | 11 | na |
| Age (years) | 14.0 (9.0) | 11 | 12.0 (10.0) | 11 | 0.1 (0.5, -0.4) |
| Pubertal stage (pre/ during/post) | 5/2/4 | 11 | 5/2/4 | 11 | na |
| Ethnicity | 1 Pakistani; 10 British | 11 | 1 Pakistani; 1 Asian, 9 British | 11 | na |
| Body composition | | | | | |
| Height SDS | 0.53 (3.1) | 11 | 0.2 (1.8) | 11 | 0.8 (0.5, -0.4) |
| Weight SDS | 1.9 (3.0) | 11 | -0.2 (1.2) | 11 | 0.5 (0.8, -0.1) |
| BMI SDS | 1.4 (3.0) | 11 | -0.5 (1.3) | 11 | 0.6 (0.8, 0.0) |
| Fat mass (%) | 29.9 (23.6) | 10 | 18.2 (7.2) | 11 | 0.5 (0.8, -0.1) |
| Fat mass (kg) | 16.0 (21.1) | 10 | 6.7 (1.3) | 11 | 0.5 (0.8, 0.0) |
| Energy expenditure | | | | | |
| Resting metabolic rate (RMR) | 1874.0 (839.0) | 10 | 1791.0 (382.0) | 9 | 0.1 (0.6,-0.4) |
| Energy intake (ad libitum meal) | | | | | |
| Energy (kJ) | 4886.0 (3426.0) | 11 | 4783.0 (2193.0) | 10 | 0.0 (0.5, -0.5) |
| Fat (g) | 50.0 (30.0) | 11 | 50.0 (21.8) | 10 | 0.0 (0.4, -0.5) |
| Fat (% energy) | 40.0 (11.0) | 11 | 38.0 (9.5) | 10 | 0.0 (0.5, -0.5) |
| CHO (g) | 148.0 (79.0) | 11 | 129.5 (71.5) | 10 | 0.1 (0.5, -0.4) |
| CHO (% energy) | 50.0 (8.0) | 11 | 45.5 (10.5) | 10 | 0.2 (0.6, -0.3) |
| Protein (g) | 28.0 (27.0) | 11 | 37.0 (13.5) | 10 | -0.2 (0.3, -0.6) |

| Protein (% energy) | 9.0 (4.0) | 11 | 11.5 (3.8) | 10 | -0.3 (0.2, -0.7) |
|---|-------------|----|-------------|----|-------------------|
| Hyperphagia questionnaire | | | | | |
| Hyperphagia: Total | 23.0 (15.0) | 11 | 16.0 (8.0) | 11 | 0.5 (0.8, 0.0) |
| Hyperphagia: behaviour | 10.0 (9.0) | 11 | 6.0 (3.0) | 11 | 0.5 (0.8, 0.0) |
| Hyperphagia: drive | 9.0 (6.0) | 11 | 7.0 (4.0) | 11 | 0.4 (0.8, -0.1) |
| Hyperphagia: severity | 4.0 (2.0) | 11 | 2.0 (1.0) | 11 | 0.7 (0.9, 0.2) |
| Adult/Child Eating Behaviour Questionnaire | | | | | |
| Enjoyment of Food | 4.7 (1.3) | 11 | 4.0 (1.8) | 11 | 0.3 (0.7, -0.2) |
| Emotional overeating | 2.3 (1.5) | 11 | 2.0 (0.9) | 11 | 0.3 (0.7, -0.2) |
| Food responsiveness | 3.5 (2.0) | 11 | 2.5 (0.7) | 11 | 0.3 (0.7, -0.3) |
| Slowness in eating | 2.5 (2.5) | 11 | 2.8 (1.8) | 11 | -0.2 (0.3, -0.6) |
| Food approach | 3.4 (1.6) | 11 | 2.7 (0.9) | 11 | 0.4 (0.7, -0.1) |
| Satiety responsiveness | 2.5 (1.4) | 11 | 3.3 (1.6) | 11 | -0.4 (0.1, -0.8) |
| Emotional undereating | 2.5 (2.1) | 11 | 3.0 (1.1) | 11 | -0.1 (0.4, -0.5) |
| Food fussiness | 2.7 (2.3) | 11 | 2.8 (1.7) | 11 | -0.2 (0.3, -0.6) |
| Food avoidance | 2.7 (0.8) | 11 | 3.0 (0.5) | 11 | -0.4 (0.1, -0.7) |
| Quality of Life (MMQL) | | | | | |
| Participant total | 65.5 (28.5) | 11 | 78.5 (20.7) | 11 | -0.3 (0.2, -0.7) |
| Participant physical | 80.0 (35.0) | 11 | 95.0 (25.0) | 11 | -0.5 (0.0, -0.8) |
| Participant emotional | 60.7 (32.1) | 11 | 71.4 (10.7) | 11 | -0.2 (0.3, -0.6) |
| Participant social | 91.7 (20.8) | 11 | 83.3 (12.5) | 11 | 0.1 (0.6, -0.4) |
| Participant school | 57.1 (39.3) | 11 | 75.0 (35.7) | 11 | -0.3 (0.2, -0.7) |
| Participant physical appearance | 50.0 (50.0) | 11 | 81.3 (56.3) | 11 | -0.2 (0.3, -0.6) |
| Parent total | 59.5 (13.8) | 9 | 83.6 (18.9) | 8 | -0.9 (-0.5, -1.0) |
| Parent physical | 45.0 (28.0) | 9 | 92.5 (20.0) | 8 | -0.8 (-0.2, -1.0) |
| Parent emotional | 64.3 (28.6) | 9 | 64.3 (8.9) | 8 | -0.1 (0.5, -0.6) |
| Parent social | 79.2 (35.4) | 9 | 91.7 (14.6) | 8 | -0.5 (0.0, -0.8) |

| I | Parent school | 46.4 (57.2) | 9 | 92.9 (18.8) | 8 | -0.8 (-0.2, -0.9) |
|---|----------------------------|-------------|---|-------------|---|-------------------|
| I | Parent physical appearance | 37.5 (59.4) | 9 | 75.0 (34.4) | 8 | -0.3 (0.3, -0.7) |

Table 5 – Relationship (Kendalls tau) between eating behaviour measures and BMI-SDS

| | COSMED full dataset RMR (kcal/day) | Energy intake (kJ) | Food Approach | Food Avoidance | Hyperphagia total score |
|--------------------------------|--|--------------------------|------------------|-------------------|----------------------------|
| Craniophary ngioma group | -0.02 | 0.27 | .55 | -0.38 | 0.43 |
| Matched controls | 0.25 | 0.41 | 0.04 | 0.11 | 0.23 |

Table 6 – Relationship (Kendalls tau) between eating behaviour measures and QoL

| | | COSMED full | Energy | | | |
|---------------------|-----------------------------|--------------|--------|----------|-----------|-------------|
| | | dataset RMR | intake | Food | Food | Hyperphagia |
| | | (kcal/day) | (kJ) | Approach | Avoidance | total score |
| Patient group | Participant reported QoL | 18 (n=10) | 0.09 | -0.08 | 0.17 | -0.11 |
| | (n=11) | | | | | |
| | Parent/carer | -0.07 | -0.09 | -0.09 | 0.42 | -0.40 |
| | reported QoL (n=9) | (n=8) | | | | |
| Matched controls | Participant | 0.37 | 0.00 | -0.34 | 0.15 | -0.39 |
| | reported QoL | (n=9) | (n=10) | | | |
| | (n=11) | | | | | |
| | Parent/carer | -0.20 | -0.26 | -0.26 | 0.04 | -0.39 |
| | reported QoL | (n=6) | | | | |
| | (n=8) | | | | | |